MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jaad.2024.09.031

Медицинская библиотека · Journal of the American Academy of Dermatology · 2024

Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial.

Yan Kexiang, Li Fuqiu, Bi Xiaodong, Han Ling, Zhang Zhenghua, Chen Rixin, Li Yuye, Zhang Litao, Wang Xiaohua, Li Linfeng, Lu Jianyun, Xu Ai'e, Yang Sen, Lu Yan, Sun Jianfang, Li Zhiming, Zhu Xiaohong, Jiang Meiying, Zhang Siping, Wang Wenqing, Li Yanling, Meng Zudong, Li Hongyi, Mou Kuanhou, Han Xiuping, Li Shanshan, Chen Aijun, Li Xin, Liu Donghua, Zhang Chunlei, Ji Chao, Wang Yu, Cheng Hao, Cui Xiaojing, Yao Xiaoyan, Bai Xiaoyan, Dong Guangchao, Xu Jinhua

СтатьяРандомизированное исследованиеКлиническое исследование III фазыМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Vunakizumab, a novel anti-interleukin-17A antibody, has shown promising efficacy for moderate-to-severe plaque psoriasis in a phase 2 trial.

OBJECTIVE

We conducted a double-blind, randomized phase 3 trial (NCT04839016) to further evaluate vunakizumab in this population.

METHODS

Six hundred ninety subjects were randomized (2:1) to receive vunakizumab 240 mg or placebo at weeks 0, 2, 4, and 8. At week 12, subjects on placebo were switched to vunakizumab 240 mg (weeks 12, 14, 16, and every 4 weeks thereafter). The co-primary endpoints were ≥90% improvement from baseline in the Psoriasis Area and Severity Index score (PASI 90) and a static Physicians Global Assessment score of 0/1 (sPGA 0/1) at week 12.

RESULTS

At week 12, the vunakizumab group showed higher PASI 90 (76.8% vs 0.9%) and sPGA 0/1 (71.8% vs 0.4%) response rates, as well as higher PASI 75 (93.6% vs 4.0%), PASI 100 (36.6% vs 0.0%), and sPGA 0 (38.2% vs 0.0%) response rates (all two-sided P < .0001 vs placebo). Efficacy was maintained through week 52 with continuous vunakizumab. Possible treatment-related serious adverse events occurred in 0.9% of vunakizumab-treated subjects.

LIMITATIONS: Chinese subjects only; no active comparator.

CONCLUSION

Vunakizumab demonstrated robust clinical response at week 12 and through week 52, with good tolerability in moderate-to-severe plaque psoriasis.

Для цитирования: Yan Kexiang, Li Fuqiu, Bi Xiaodong, Han Ling, Zhang Zhenghua, Chen Rixin, Li Yuye, Zhang Litao, Wang Xiaohua, Li Linfeng, Lu Jianyun, Xu Ai'e, Yang Sen, Lu Yan, Sun Jianfang, Li Zhiming, Zhu Xiaohong, Jiang Meiying, Zhang Siping, Wang Wenqing, Li Yanling, Meng Zudong, Li Hongyi, Mou Kuanhou, Han Xiuping, Li Shanshan, Chen Aijun, Li Xin, Liu Donghua, Zhang Chunlei, Ji Chao, Wang Yu, Cheng Hao, Cui Xiaojing, Yao Xiaoyan, Bai Xiaoyan, Dong Guangchao, Xu Jinhua. Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial.. Journal of the American Academy of Dermatology. 2024. DOI: 10.1016/j.jaad.2024.09.031.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.